Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
Dominika Wojewska, Arjan Kortholt
Biomolecules (2021) Vol. 11, Iss. 8, pp. 1101-1101
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

The understanding of Parkinson's disease through genetics and new therapies
Olivier Uwishema, Helen Onyeaka, Rawa Badri, et al.
Brain and Behavior (2022) Vol. 12, Iss. 5
Open Access | Times Cited: 49
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Giuseppe Arena, Karan Sharma, Gideon Agyeah, et al.
Current Neurology and Neuroscience Reports (2022) Vol. 22, Iss. 8, pp. 427-440
Open Access | Times Cited: 48
In silico screening of LRRK2 WDR domain inhibitors using deep docking and free energy simulations
Evgeny Gutkin, Filipp Gusev, Francesco Gentile, et al.
Chemical Science (2024) Vol. 15, Iss. 23, pp. 8800-8812
Open Access | Times Cited: 9
Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases
Hossein Mousavi, Mehdi Rimaz, Behzad Zeynizadeh
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 9, pp. 1828-1881
Closed Access | Times Cited: 8
New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin
Konstantin Senkevich, Uladzislau Rudakou, Ziv Gan‐Or
Neuropharmacology (2021) Vol. 202, pp. 108822-108822
Closed Access | Times Cited: 53
Research progress of PROTACs for neurodegenerative diseases therapy
Zhifang Cai, Zunhua Yang, Huilan Li, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107386-107386
Closed Access | Times Cited: 8
LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting
Yulan Xiong, Jianzhong Yu
Trends in Molecular Medicine (2024) Vol. 30, Iss. 10, pp. 982-996
Closed Access | Times Cited: 7
Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
Thiviyadarshini Rajasegaran, Chee Wun How, Anoosha Saud, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 451-451
Open Access | Times Cited: 16
The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson’s Disease
Xu Tang, Shuaishuai Xing, Mingkang Ma, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2282-2307
Closed Access | Times Cited: 14
Recombinant Antibody Fragments for Immunotherapy of Parkinson’s Disease
Karen Manoutcharian, Goar Gevorkian
BioDrugs (2024) Vol. 38, Iss. 2, pp. 249-257
Open Access | Times Cited: 5
Subpocket Similarity-Based Hit Identification for Challenging Targets: Application to the WDR Domain of LRRK2
Merveille Eguida, Guillaume Bret, François Sindt, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 13, pp. 5344-5355
Open Access | Times Cited: 5
Pipeline of Pharmacotherapy in Parkinson’s Disease
Florian Brugger, Stefan Hägele-Link
Cambridge University Press eBooks (2025), pp. 290-305
Closed Access
La maladie de Parkinson : de la génétique aux thérapies ciblées
Guillaume Cogan, Alexis Brice
Comptes Rendus Biologies (2025) Vol. 348, Iss. G1, pp. 21-33
Open Access
Exploring the Impact of LRRK2 WD40 G2294R Mutation on Conformation and Dimerisation Dynamics: Insights From Molecular Dynamics Simulation
Chuancheng Wei, Choon Han Heh, Sek Peng Chin
Journal of Cellular Biochemistry (2025) Vol. 126, Iss. 2
Closed Access
LRRK2 reduces the sensitivity to TKI and PD-1 blockade in ccRCC via activating LPCAT1
Yulong Hong, Weidong Li, Zhuo Xing, et al.
Oncogene (2025)
Closed Access
The Multifaceted Role of LRRK2 in Parkinson’s Disease
Dong Hwan Ho, Sun Jung Han, Ilhong Son
Brain Sciences (2025) Vol. 15, Iss. 4, pp. 407-407
Open Access
Regulation of LRRK2 mRNA stability by ATIC and its substrate AICAR through ARE‐mediated mRNA decay in Parkinson's disease
Qinfang Liu, Dong Zhu, Naren Li, et al.
The EMBO Journal (2023) Vol. 42, Iss. 15
Closed Access | Times Cited: 9
Genetics of Parkinson's disease: Dominant forms and GBA
Philippe A. Salles, José M. Tirapegui, Pedro Chaná‐Cuevas
Neurology Perspectives (2024) Vol. 4, Iss. 3, pp. 100153-100153
Open Access | Times Cited: 3
Regulation of Leucine-Rich Repeat Kinase 2 by inflammation and IL-4
Dina Dikovskaya, Rebecca Pemberton, Matthew Taylor, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors
Kaitlyn M. Logan, Will Kaplan, Vladimir Simov, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 18, pp. 16807-16819
Closed Access | Times Cited: 3
Tratamiento farmacológico de los síntomas motores de la enfermedad de Parkinson: actualización y recomendaciones de un experto
Jaime Kulisevsky
Revista de Neurología (2022) Vol. 75, Iss. S04, pp. S1-S1
Open Access | Times Cited: 14
Intramolecular feedback regulation of the LRRK2 Roc G domain by a LRRK2 kinase dependent mechanism
Bernd K. Gilsbach, Franz Y. Ho, Benjamin Riebenbauer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 8
LRRK2 and Proteostasis in Parkinson’s Disease
María Dolores Pérez‐Carrión, Inmaculada Posadas, Javier Solera, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6808-6808
Open Access | Times Cited: 12
The autophagy–lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson’s disease
Fengjuan Jiao, Lingyan Meng, Kang Du, et al.
Neural Regeneration Research (2024) Vol. 20, Iss. 1, pp. 139-158
Open Access | Times Cited: 2
LRRK2 kinase activity restricts NRF2-dependent mitochondrial protection in microglia
Chi Gidley Weindel, Lily M Ellzey, Aja K. Coleman, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top